All In Biotech

Drug Trial Radar · NCT04760769

Open-label Trial in Parkinson's Disease (PD)

58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

992

Actual

Start

Feb 24, 2021

Primary completion

Dec 1, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.

Conditions

  • Parkinson Disease

Interventions

  • TavapadonDrug

    Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: 62 Weeks
  2. Number of Participants Who Discontinued Study TreatmentTime frame: 62 Weeks
  3. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS)Time frame: 58 Weeks
  4. Epworth Sleepiness Scale (ESS)Time frame: 58 Weeks
  5. Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 60 Weeks
  6. Study Medication Withdrawal Questionnaire (SMWQ)Time frame: 60 Weeks
  7. Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and IIITime frame: 60 Weeks
  8. Change From Baseline in the Hauser diaryTime frame: 58 Weeks
  9. Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) IndexTime frame: Baseline (Day 1), Weeks 32 and 58
  10. Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scores (VAS)Time frame: Baseline (Day 1), Weeks 32 and 58

Locations

140 sites in 14 countries. Site status is shown where the registry gives one.

  • Birmingham, Alabama

    Birmingham, Alabama

  • Pheonix, Arizona

    Phoenix, Arizona

  • Little Rock, Arkansas

    Little Rock, Arkansas

  • Fountain Valley, California

    Fountain Valley, California

  • Fresno, California

    Fresno, California

  • Los Angeles, California

    Los Angeles, California

  • Pasadena, California

    Pasadena, California

  • Reseda, California

    Reseda, California

  • Englewood, Colorado

    Englewood, Colorado

  • Florida, United States

    Adventura, Florida

  • Boca Raton, Florida

    Boca Raton, Florida

  • Coral Springs, Florida

    Coral Springs, Florida

  • Maitland, Florida

    Maitland, Florida

  • Naples, Florida

    Naples, Florida

  • Ocala, Florida

    Ocala, Florida

  • Port Charlotte, Florida

    Port Charlotte, Florida

  • Port Orange, Florida

    Port Orange, Florida

  • Tampa, Florida

    Tampa, Florida

  • Winter Park, Florida

    Winter Park, Florida

  • Augusta, Georgia

    Augusta, Georgia

  • Chicago, Illinois

    Chicago, Illinois

  • Winfield, Illinois

    Winfield, Illinois

  • Kansas City

    Kansas City, Kansas

  • Lexington, Kentucky

    Lexington, Kentucky

  • Scarborough, Maine

    Scarborough, Maine

  • Boston, Massachusettes

    Boston, Massachusetts

  • Lawrence, Massachusetts

    Lawrence, Massachusetts

  • East Lansing, Michigan

    East Lansing, Michigan

  • West Bloomfield

    West Bloomfield, Michigan

  • Las Vegas, Nevada

    Las Vegas, Nevada

  • Camden, New Jersey

    Camden, New Jersey

  • Albany, New York

    Albany, New York

  • Syracuse, New York

    Syracuse, New York

  • Asheville, North Carolina

    Asheville, North Carolina

  • Durham, North Carolina

    Durham, North Carolina

  • Cincinnati, Ohio

    Cincinnati, Ohio

  • Cleveland, Ohio

    Cleveland, Ohio

  • Columbus, Ohio

    Columbus, Ohio

  • Dayton, Ohio

    Dayton, Ohio

  • Toledo, Ohio

    Toledo, Ohio

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.